Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

Completed

• Conditions: Metastatic Clear Cell Renal Cell Carcinoma

• Registration Number: NCT02848768
• Lead Sponsor: Rennes University Hospital

Brief Summary

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12
• Primary Completion: 2015-03
• Status Verified: 2016-07
• Study First Submitted: 2016-07-26
• Study First Submitted QC: 2016-07-27
• Last Update Submitted: 2016-07-27
• Study First Posted: 2016-07-28
• Last Update Posted: 2016-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• patients with metastatic ccRCC
• Underwent nephrectomy at the University Hospital of Rennes
• treated by sunitinib first line treatment

Exclusion Criteria

• translocation renal cell carcinoma
• other targeted therapies before the sunitinib

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary refractory patients (Progression Free Survival (PFS)	at 3 months

Trial Locations

Locations (1)

CHU de Rennes; 🇫🇷 Rennes, France